IgM promotes antitumor immunity to a Tn-expressing solid tumor
Open Access
- 17 September 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015127
Abstract
Background: Altered O-glycosylation is a hallmark of many adenocarcinomas and is often characterized by expression of the Tn antigen. However, the role of B cells in protection against Tn-expressing solid tumors remains poorly understood. Methods: We generated a colorectal tumor cell line (CMT93) lacking Cosmc , resulting in high Tn expression. Using mice with defined B-cell abnormalities, including deficiencies in B cells, IgM secretion, natural IgM, and B-cell receptor (BCR) repertoire diversity, we investigated the contribution of B cells and secreted antibody to immunity against Tn-expressing colorectal tumors. Results: Cosmc -deficient tumors grew more rapidly than parental tumors, and IgM deposition was observed within tumors from wild-type mice, suggesting a potential role for antibody in antitumor defense. Tumor-reactive serum IgM, including Tn-reactive IgM, was present in naïve mice. B cell-deficient muMT, V H B 1-8 transgenic mice with a restricted BCR repertoire, CD19 −/− mice deficient in natural IgM, and μS −/− mice unable to secrete IgM, lacked tumor-reactive IgM and showed increased tumor burdens, suggesting a protective role for secreted tumor-reactive IgM. Lack of tumor-reactive IgM in V H B 1-8 transgenic and μS −/− mice was associated with significant alterations in tumor-infiltrating leukocyte composition. Relative to wild-type mice, tumors from V H B 1-8 transgenic and μS −/− mice exhibited significantly increased PD-L1 hi Ly6G + Ly6C − CD11b + myeloid cells, but reduced B, T, and natural killer cells, along with reduced major histocompatibility complex class II expression on tumor-associated dendritic cells. Moreover, tumor draining lymph nodes from V H B 1-8 transgenic and μS −/− mice showed significant reductions in antibody-secreting cells, including IgG + plasmablasts, which corresponded with decreased IgM and IgG deposition on tumors. Conclusions: These findings support a role for B cells and secreted IgM in restraining the growth of Tn-expressing solid tumors and shaping antitumor immunity against tumors with aberrant O-glycosylation.Keywords
Funding Information
- National Cancer Institute (P30CA012197)
- National Cancer Institute (R01CA272724)
- National Institute of Allergy and Infectious Diseases (F31AI194729)
- National Institute of Allergy and Infectious Diseases (T32 AI007401)
This publication has 49 references indexed in Scilit:
- Understanding IgM Structure and Biology to Engineer New Antibody TherapeuticsBioDrugs, 2025
- Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancersImmunity, 2023
- Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatmentsCellular Immunology, 2021
- Mouse model of colorectal cancer: Orthotopic co-implantation of tumor and stroma cells in cecum and rectumSTAR Protocols, 2021
- A TLR4–TRIF-dependent signaling pathway is required for protective natural tumor-reactive IgM production by B1 cellsCancer Immunology, Immunotherapy, 2020
- B cell regulation in cancer and anti-tumor immunityCellular & Molecular Immunology, 2017
- The Tn Antigen—Structural Simplicity and Biological ComplexityAngewandte Chemie International Edition, 2011
- B-1a and B-1b Cells Exhibit Distinct Developmental Requirements and Have Unique Functional Roles in Innate and Adaptive Immunity to S. pneumoniaeImmunity, 2005
- Role of antigen receptor affinity in T cell–independent antibody responses in vivoNature Immunology, 2002
- Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapyJournal of Molecular Medicine, 1997